Meiji Seika Pharma Submitted New Drug Application to Manufacture and Market ARCT-154 in Japan
Meiji Seika Pharma Co., Ltd. submitted a New Drug Application to manufacture and market ARCT-154 for primary immunization to prevent COVID-19 in adults (two doses of ARCT-154) in Japan. ARCT-154, is a next generation mRNA vaccine against COVID-19, was developed by Arcturus Therapeutics Inc and in April, Meiji obtained exclusive rights to distribute ARCT-154 in Japan from CSL Seqirus.
Press release of Meiji Holdings;
ARCALIS is currently building the mRNA drug manufacturing facility in Minamisoma City, Fukushima Prefecture, where we can manufacture ARCT-154 from drug substance to drug product in Japan.